- Home
- ZLAB vs BUSE Comparison
ZLAB vs BUSE Comparison
Compare ZLAB & BUSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZLAB | BUSE |
|---|---|---|
| Founded | 2013 | 1868 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | BUSE |
|---|---|---|
| Price | $25.52 | $30.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $49.60 | $27.17 |
| AVG Volume (30 Days) | ★ 983.0K | 796.6K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.04% |
| EPS Growth | ★ 38.46 | N/A |
| EPS | N/A | ★ 1.20 |
| Revenue | $460,156,000.00 | ★ $719,584,000.00 |
| Revenue This Year | $9.75 | $23.84 |
| Revenue Next Year | $26.03 | $3.82 |
| P/E Ratio | ★ N/A | $25.90 |
| Revenue Growth | 15.33 | ★ 55.66 |
| 52 Week Low | $15.96 | $22.00 |
| 52 Week High | $35.45 | $31.70 |
Technical Indicators
Market Signals| Indicator | ZLAB | BUSE |
|---|---|---|
| Relative Strength Index (RSI) | 73.93 | 55.79 |
| Support Level | $16.98 | $30.61 |
| Resistance Level | $26.66 | $31.70 |
| Average True Range (ATR) | 1.18 | 0.45 |
| MACD | 0.57 | -0.08 |
| Stochastic Oscillator | 87.07 | 25.69 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.